Schmeling et al. observed that children with JIA treated with the TNF-blocker etanercept displayed improvement in growth parameters, IGF-1 and IGFBP3 levels; specifically, growth velocity increased from 3.7 ± 1.2 cm before therapy to 7.6 ± 1.2 cm during the first year of treatment [93]. This evidence concerns the gene IGF1 and juvenile idiopathic arthritis.